Trials soon ready
Clinical trials expected to report results within the next 6 months, ranked by potential. Each trial shows its estimated finish date — explained in plain language.
Showing the top 50 of 1695 trials in this window.
-
One-Time gene therapy aims to restore muscle in boys with duchenne
Disease control OngoingRGX-202 is a gene therapy designed to deliver a transgene for a novel microdystrophin that includes functional elements of naturally-occurring dystrophin including the C-Terminal (CT) domain. This is a multicenter, open-label dose evaluation clinical study to assess the safety, …
Results expected Sep 2026 (estimated)
Phase: PHASE2, PHASE3 • Sponsor: REGENXBIO Inc. • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
RegenxBio Inc. · RGNX NASDAQ Trade on eToro (ad)Reward if it works Very highA late-stage readout — success would transform the company.
Risk to the company HighA small company — one failure carries real weight.
-
Can engineered immune cells outsmart Hard-to-Treat blood cancers?
⭐️ CURE ⭐️ OngoingThe purpose of this study is to evaluate the safety and preliminary activity of ARC-T cells and SPRX002 in participants with relapsed or refractory acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS)
Results expected Oct 2026 (estimated)
Phase: PHASE1 • Sponsor: Arcellx, Inc. • Aim: ⭐️ CURE ⭐️
Last updated Aug 13, 2026 00:00 UTC
Gilead Sciences, Inc. · GILD NASDAQ Trade on eToro (ad)Reward if it works Very highAiming at a cure or vaccine; success would transform the company.
Risk to the company ModerateA small company — one failure carries real weight.
-
Could a Virus-Like particle vaccine outsmart polio?
⭐️ VACCINE ⭐️ OngoingThis is a phase I/II randomized, double-blind, and positive-controlled study. Participants in the phase I toddler group will receive 1 dose of either high dose VLP-Polio (Dose H) or control vaccine in a ratio of 3:1. The phase I infant cohort will have 4 arms randomly assigned to…
Results expected Oct 2026 (estimated)
Phase: PHASE1, PHASE2 • Sponsor: CanSino Biologics Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated Aug 08, 2026 00:03 UTC
CanSino Biologics Inc. · 6185 HKEXReward if it works Very highAiming at a cure or vaccine; success would transform the company.
Risk to the company HighA small company — one failure carries real weight.
-
Could one drug replace the standard triple therapy for rectal cancer?
Disease control OngoingThe purpose of this study is to investigate dostarlimab monotherapy in participants with locally advanced Mismatch-repair deficient (dMMR)/Microsatellite instability-high (MSI-H) rectal cancer who have received no prior treatment. Participants who achieve complete clinical respon…
Results expected Nov 2026 (estimated)
Phase: PHASE2 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
GSK · GSK NYSE Trade on eToro (ad)Reward if it works HighAn incremental result rather than a breakthrough.
Risk to the company LowA large company running many trials — it absorbs a failure here.
-
New hope for advanced breast cancer: targeted drug combo tested in major trial
Disease control OngoingThe study will evaluate the efficacy and safety of trastuzumab deruxtecan (also known as T-DXd, DS-8201a), either alone or in combination with pertuzumab, in treating patients with Human epidermal growth factor receptor 2 (HER2)-positive breast cancer as a first line of treatment…
Results expected Nov 2026 (estimated)
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
AstraZeneca · AZN NASDAQ Trade on eToro (ad)Reward if it works HighA late-stage readout — success would still be major news.
Risk to the company LowA large company running many trials — it absorbs a failure here.
-
Major RSV vaccine trial for seniors nears completion
⭐️ VACCINE ⭐️ OngoingEfficacy Study: This randomized, double-blinded, placebo-controlled Phase 3 study is designed to assess the safety, immunogenicity, and efficacy of a single dose of RSVpreF in the prevention of LRTI-RSV in adults: * At a dose of 120µg. * In adults 60 years of age and older. * Th…
Results expected Jan 2027 (estimated)
Phase: PHASE3 • Sponsor: Pfizer • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 09:00 UTC
Pfizer · PFE NYSE Trade on eToro (ad)Reward if it works Very highA late-stage readout — success would still be major news.
Risk to the company LowA large company running many trials — it absorbs a failure here.
-
New mRNA vaccine aims to stop the stomach flu
⭐️ VACCINE ⭐️ OngoingThe primary objectives of this study are to evaluate the safety and reactogenicity of mRNA-1403, and to demonstrate the efficacy of mRNA-1403 to prevent protocol-defined moderate or severe norovirus acute gastroenteritis (AGE) associated with vaccine matched genotypes.
Results expected Feb 2027 (estimated)
Phase: PHASE3 • Sponsor: ModernaTX, Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:33 UTC
Moderna, Inc. · MRNA NASDAQ Trade on eToro (ad)Reward if it works Very highA late-stage readout — success would still be major news.
Risk to the company LowA large company running many trials — it absorbs a failure here.
-
New drug aims to outdo chemo for lung cancer patients Who've run out of options
Disease control OngoingThis trial is a registered phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-B01D1 in patients with locally advanced or metastatic non-squamous non-small cell lung cancer with EGFR-sensitive mutations after EGFR-TKI failure.
Results expected Aug 2026 (estimated)
Phase: PHASE3 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
Sichuan Baili Pharmaceutical Co., Ltd. · 688506 SSEReward if it works HighA late-stage readout — success would transform the company.
Risk to the company HighA small company — one failure carries real weight.
-
Gene therapy shot could end monthly eye injections for wet AMD
Disease control OngoingThis interventional study is being conducted with an investigational gene therapy treatment called ABBV-RGX-314 (also known as RGX-314) and is being developed as a potential one-time gene therapy treatment for neovascular (wet) age-related macular degeneration (wet AMD or nAMD). …
Results expected Aug 2026 (estimated)
Phase: PHASE2 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
AbbVie · ABBV NYSE Trade on eToro (ad)Reward if it works ModerateAn incremental result rather than a breakthrough.
Risk to the company Very lowA large company running many trials — it absorbs a failure here.
-
New monthly shot could stop COVID-19 before it starts
Prevention OngoingThe main purpose of this study is to test an investigational drug known as VYD2311, which is being developed to lower the risk of getting COVID-19. VYD2311 is a monoclonal antibody that attaches to the virus that causes COVID-19 and helps block it from entering your cells. It is …
Results expected Aug 2026 (estimated)
Phase: PHASE3 • Sponsor: Invivyd, Inc. • Aim: Prevention
Last updated Jun 27, 2026 13:06 UTC
InVivyd · IVVD NASDAQ Trade on eToro (ad) -
New drug combo aims to outperform standard immunotherapy in stomach cancer
Disease control OngoingThis randomized Phase 3 open-label study will compare the efficacy of the T-cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif (ITIM) domain (TIGIT) monoclonal antibody domvanalimab, the anti programmed cell death protein 1 (PD-1) monoclonal antibody zimbereli…
Results expected Aug 2026 (estimated)
Phase: PHASE3 • Sponsor: Arcus Biosciences, Inc. • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
Arcus Biosciences, Inc. · RCUS NYSE Trade on eToro (ad)Reward if it works HighA late-stage readout — success would transform the company.
Risk to the company HighA small company — one failure carries real weight.
-
New COVID-19 vaccine candidate tested alone or as a booster with mRNA shots
⭐️ VACCINE ⭐️ Recruiting nowThe main purposes of this research study are to measure the safety (whether it causes any side effects), tolerability (if it does cause any side effects, how well your body is able to handle them), and reactions, both local at the injection site and systemic, that may occur in th…
Results expected Aug 2026 (estimated)
Phase: PHASE3 • Sponsor: Invivyd, Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 14:00 UTC
InVivyd · IVVD NASDAQ Trade on eToro (ad) -
New antibody drug aims to tame ulcerative colitis in major trial
Disease control OngoingThe purpose of this protocol is to evaluate the efficacy of tulisokibart in participants with moderately to severely active ulcerative colitis. Study 1's primary hypotheses are that at least 1 tulisokibart dose level is superior to Placebo in the proportion of participants achiev…
Results expected Aug 2026 (estimated)
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
Merck & Co., Inc. · MRK NYSE Trade on eToro (ad)Reward if it works HighA late-stage readout — success would still be major news.
Risk to the company LowA large company running many trials — it absorbs a failure here.
-
Gene-Editing shot could slash cholesterol for good
Disease control Recruiting nowVT-10201 is an Open-label, Phase 1b, Single-ascending Dose Study That Will Evaluate the Safety of VERVE-102 Administered to Patients With Heterozygous Familial Hypercholesterolemia (HeFH) or Premature Coronary Artery Disease (CAD) Who Require Additional Lowering of LDL-C. VERVE-1…
Results expected Aug 2026 (estimated)
Phase: PHASE1 • Sponsor: Verve Therapeutics, Inc. • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
Eli Lilly and Company · LLY NYSE Trade on eToro (ad)Reward if it works HighAn incremental result rather than a breakthrough.
Risk to the company HighA small company — one failure carries real weight.
-
Monthly shot could free kids with hemophilia from frequent infusions
Disease control OngoingPrimary Objective: \- To confirm appropriate dose levels of fitusiran when administered to male pediatric participants (ages 1 to \<12 years of age) with severe hemophilia A or B Secondary Objectives: * To characterize the safety and tolerability * To determine fitusiran plasm…
Results expected Aug 2026 (estimated)
Phase: PHASE2, PHASE3 • Sponsor: Genzyme, a Sanofi Company • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
Sanofi S.A. · SNY NASDAQ Trade on eToro (ad)Reward if it works HighA late-stage readout — success would still be major news.
Risk to the company LowA large company running many trials — it absorbs a failure here.
-
New drug aimed at tough breast cancer enters final testing phase
Disease control OngoingThis is a Phase III, randomized, open-label, 2-arm, multicentre, international study assessing the efficacy and safety of FDA018-ADC compared with Investigator's Choice Chemotherapy(ICC) in participants with locally recurrent inoperable or metastatic Triple-negative Breast Cancer…
Results expected Aug 2026 (estimated)
Phase: PHASE3 • Sponsor: Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. · 1349 HKEXReward if it works HighA late-stage readout — success would transform the company.
Risk to the company HighA small company — one failure carries real weight.
-
New drug duo aims to stall advanced breast cancer
Disease control OngoingThe study is intended to show superiority of AZD9833 in combination with palbociclib (a CDK4/6 inhibitor) versus anastrozole (an aromatase inhibitor) and palbociclib as the initial treatment of patients with hormone receptor-positive (ER-positive), human epidermal growth factor 2…
Results expected Aug 2026 (estimated)
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
AstraZeneca · AZN NASDAQ Trade on eToro (ad)Reward if it works HighA late-stage readout — success would still be major news.
Risk to the company LowA large company running many trials — it absorbs a failure here.
-
New hope for stomach cancer: targeted drug shows promise in Late-Stage trial
Disease control OngoingThis study will evaluate the efficacy and safety of trastuzumab deruxtecan (T-DXd) compared with ramucirumab and paclitaxel (Ram + PTX) in participants with HER2-positive gastric or gastro-esophageal junction (GEJ) adenocarcinoma who have progressed on or after a trastuzumab-cont…
Results expected Aug 2026 (estimated)
Phase: PHASE3 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
Daiichi Sankyo Company, Limited · DSNKY OTCReward if it works HighA late-stage readout — success would still be major news.
Risk to the company LowA large company running many trials — it absorbs a failure here.
-
New combo therapy shows promise for tough-to-treat lymphoma
Disease control OngoingThis is a phase 3, multicenter, randomized, double-blind, placebo-controlled trial designed to compare the efficacy and safety of the humanized monoclonal anti CD19 antibody tafasitamab plus lenalidomide in addition to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine…
Results expected Sep 2026 (estimated)
Phase: PHASE3 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
Incyte · INCY NASDAQ Trade on eToro (ad)Reward if it works HighA late-stage readout — success would still be major news.
Risk to the company LowA large company running many trials — it absorbs a failure here.
-
One-Time gene therapy could free hemophilia patients from frequent infusions
Disease control OngoingIn this study researchers want to gather more information about safety and effectiveness of BAY 2599023 (DTX201), a drug therapy that delivers the human factor VIII gene into the human body by use of a viral vector to treat the disease. By replacing the defective gene with a heal…
Results expected Sep 2026 (estimated)
Phase: PHASE1, PHASE2 • Sponsor: Bayer • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
Bayer AG · BAYN XETRAReward if it works ModerateAn incremental result rather than a breakthrough.
Risk to the company Very lowA large company running many trials — it absorbs a failure here.
-
Could this Stem-Cell infusion end insulin shots for diabetics with kidney transplants?
Disease control Recruiting nowThis study will evaluate the efficacy, safety, and tolerability of VX-880 in participants with Type 1 Diabetes (TID) with a kidney transplant.
Results expected Sep 2026 (estimated)
Phase: PHASE3 • Sponsor: Vertex Pharmaceuticals Incorporated • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
Vertex Pharmaceuticals Incorporated · VRTX NASDAQ Trade on eToro (ad)Reward if it works HighA late-stage readout — success would still be major news.
Risk to the company LowA large company running many trials — it absorbs a failure here.
-
Gene therapy slows vision loss in stargardt disease trial
Disease control OngoingPhase 2/3 Pivotal Confirmatory Clinical Trial is a randomized, outcome assessor-masked, multicenter study, that will enroll fifty-one (51) subjects. Subjects will be enrolled in a 2:1 ratio to either the treatment group (n=34 subjects) or to an untreated control group (n=17 subje…
Results expected Sep 2026 (estimated)
Phase: PHASE2, PHASE3 • Sponsor: Ocugen • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
Ocugen · OCGN NASDAQ Trade on eToro (ad)Reward if it works Very highA late-stage readout — success would transform the company.
Risk to the company HighA small company — one failure carries real weight.
-
New gene therapy targets rare, aggressive ALS
Disease control OngoingThis is the study of AMT-162 in Participants with SOD1-ALS and is designed to evaluate the safety, tolerability, and exploratory efficacy of intrathecally administered gene therapy AMT-162. AMT-162-001 is a Phase 1/2, multi-center, single ascending dose study.
Results expected Sep 2026 (estimated)
Phase: PHASE1, PHASE2 • Sponsor: UniQure Biopharma B.V. • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
uniQure · QURE NASDAQ Trade on eToro (ad)Reward if it works HighAn incremental result rather than a breakthrough.
Risk to the company ModerateA small company — one failure carries real weight.
-
New drug cocktail aims to stall lung cancer progression
Disease control OngoingThis is a Phase III, randomised, double-blind, multicentre, international study assessing the efficacy and safety of durvalumab (MEDI4736) in combination with oleclumab (MEDI9447) or durvalumab (MEDI4736) with monalizumab (IPH2201) in adults with locally advanced (Stage III), unr…
Results expected Sep 2026 (estimated)
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
AstraZeneca · AZN NASDAQ Trade on eToro (ad)Reward if it works HighA late-stage readout — success would still be major news.
Risk to the company LowA large company running many trials — it absorbs a failure here.
-
New hope for EGFR lung cancer: Dato-DXd combo tested in phase 3 trial
Disease control Recruiting nowThis study will assess the effect of Dato-DXd in combination with osimertinib or Dato-DXd monotherapy versus platinum-based doublet chemotherapy in terms of progression-free survival (PFS).
Results expected Sep 2026 (estimated)
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
AstraZeneca · AZN NASDAQ Trade on eToro (ad)Reward if it works HighA late-stage readout — success would still be major news.
Risk to the company LowA large company running many trials — it absorbs a failure here.
-
New drug cocktail targets Hard-to-Treat lung cancer mutation
Disease control OngoingStudy CA239-0010 is an open-label, Phase 2 clinical trial evaluating the clinical efficacy of adagrasib in combination with pembrolizumab and chemotherapy in the first-line setting for patients with advanced NSCLC with TPS ≥ 1%, TPS \<50% and KRAS G12C mutation
Results expected Sep 2026 (estimated)
Phase: PHASE2 • Sponsor: Mirati Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
Bristol-Myers Squibb Company · BMY NYSE Trade on eToro (ad)Reward if it works HighAn incremental result rather than a breakthrough.
Risk to the company ModerateA small company — one failure carries real weight.
-
Can a new targeted drug outperform the current standard for HER2-Positive breast cancer?
Disease control OngoingThis study is a registered phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-M07D1 in patients with unresectable locally advanced or metastatic HER2-positive breast cancer who had failed previous treatment with taxanes and trastuzumab.
Results expected Oct 2026 (estimated)
Phase: PHASE3 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
Sichuan Baili Pharmaceutical Co., Ltd. · 688506 SSEReward if it works HighA late-stage readout — success would transform the company.
Risk to the company HighA small company — one failure carries real weight.
-
One-Shot gene therapy could end monthly eye injections for wet AMD
Disease control OngoingABBV-RGX-314 (also known as RGX-314 and surabgene lomparvovec (sura-vec)) is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet AMD). Wet AMD is characterized by loss of vision due to new, leaky blood vess…
Results expected Oct 2026 (estimated)
Phase: PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
AbbVie · ABBV NYSE Trade on eToro (ad)Reward if it works HighA late-stage readout — success would still be major news.
Risk to the company LowA large company running many trials — it absorbs a failure here.
-
New RSV vaccine candidate aims to shield older adults from severe lung infections
⭐️ VACCINE ⭐️ Recruiting nowThis Phase I/II study is to characterize the safety and immunogenicity of 2 dose levels of AZD6489, an investigational RSV recombinant prefusion F protein VLP vaccine.
Results expected Oct 2026 (estimated)
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: ⭐️ VACCINE ⭐️
Last updated Jul 23, 2026 00:00 UTC
AstraZeneca · AZN NASDAQ Trade on eToro (ad)Reward if it works HighAiming at a cure or vaccine; success would still be major news.
Risk to the company Very lowA large company running many trials — it absorbs a failure here.
-
Kidney cancer combo aims to stop recurrence after surgery
Disease control OngoingThe purpose of this study is to assess the efficacy and safety of oral belzutifan (MK-6482) plus intravenous (IV) pembrolizumab (MK-3475) compared to placebo plus pembrolizumab, in the adjuvant treatment of Clear Cell Renal Cell Carcinoma (ccRCC) post nephrectomy. The primary st…
Results expected Oct 2026 (estimated)
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
Merck & Co., Inc. · MRK NYSE Trade on eToro (ad)Reward if it works HighA late-stage readout — success would still be major news.
Risk to the company LowA large company running many trials — it absorbs a failure here.
-
New pill takes on chemo for rare lung cancer
Disease control OngoingThe purpose of this study is to compare effectiveness of TAK-788 as first-line treatment with that of platinum-based chemotherapy in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors has epidermal growth factor receptor (EGFR) exon 2…
Results expected Oct 2026 (estimated)
Phase: PHASE3 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
Takeda · TAK NYSE Trade on eToro (ad)Reward if it works HighA late-stage readout — success would still be major news.
Risk to the company LowA large company running many trials — it absorbs a failure here.
-
Gene therapy injection aims to repair failing hearts
Disease control OngoingThis is a Phase 2 adaptive, double-blinded, placebo-controlled, randomized, multi-center trial study to evaluate the safety and efficacy of a single dose of AB-1002, administered via antegrade intracoronary artery infusion, in males and females age \>18 years with non-ischemic ca…
Results expected Oct 2026 (estimated)
Phase: PHASE2 • Sponsor: AskBio Inc • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
Bayer AG · BAYN XETRAReward if it works ModerateAn incremental result rather than a breakthrough.
Risk to the company LowA large company running many trials — it absorbs a failure here.
-
New drug duo aims to slow advanced lung cancer in first-line trial
Disease control OngoingThe aim of the study is to evaluate the efficacy and safety of SKB264 in combination with pembrolizumab as firstline treatment for patients with PD-L1-positive locally advanced or metastatic non-small cell lung cancer (NSCLC).
Results expected Nov 2026 (estimated)
Phase: PHASE3 • Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · 6990 HKEXReward if it works HighA late-stage readout — success would still be major news.
Risk to the company ModerateA mid-sized company with other programmes alongside this one.
-
New obesity drug retatrutide takes on tirzepatide in major trial
Disease control OngoingThe main purpose of this study is to evaluate the efficacy and safety of retatrutide compared to tirzepatide in adults who have obesity. The study will last about 89 weeks.
Results expected Nov 2026 (estimated)
Phase: PHASE3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
Eli Lilly and Company · LLY NYSE Trade on eToro (ad)Reward if it works HighA late-stage readout — success would still be major news.
Risk to the company LowA large company running many trials — it absorbs a failure here.
-
New drug hope for Tough-to-Treat throat cancer
Disease control OngoingA phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-B01D1 in patients with recurrent or metastatic nasopharyngeal carcinoma who had failed at least two lines of platinum-based chemotherapy after receiving PD-1/PD-L1 monoclonal antibody…
Results expected Nov 2026 (estimated)
Phase: PHASE3 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
Sichuan Baili Pharmaceutical Co., Ltd. · 688506 SSEReward if it works HighA late-stage readout — success would transform the company.
Risk to the company HighA small company — one failure carries real weight.
-
New pill aims to cut stroke risk without the bleeding worry
Disease control OngoingThe purpose of this study is to evaluate whether milvexian compared to placebo reduce the risk of recurrent ischemic stroke.
Results expected Nov 2026 (estimated)
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
Johnson & Johnson · JNJ NYSE Trade on eToro (ad)Reward if it works HighA late-stage readout — success would still be major news.
Risk to the company LowA large company running many trials — it absorbs a failure here.
-
New hope for Hard-to-Treat breast cancer: Head-to-Head drug trial launches
Disease control OngoingThis is a Phase III, multicenter, randomized, open-label, global study designed to evaluate the efficacy and safety of inavolisib plus fulvestrant compared with alpelisib plus fulvestrant in patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (H…
Results expected Nov 2026 (estimated)
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
Roche Holding AG · RHHBY OTCReward if it works HighA late-stage readout — success would still be major news.
Risk to the company LowA large company running many trials — it absorbs a failure here.
-
Immunotherapy plus chemo shows promise in advanced uterine cancer trial
Disease control OngoingThis is a 2 part study. Part 1 is to evaluate the efficacy and safety of dostarlimab plus carboplatin-paclitaxel followed by dostarlimab versus placebo plus carboplatin-paclitaxel followed by placebo; and Part 2 is to evaluate the efficacy and safety of dostarlimab plus carboplat…
Results expected Nov 2026 (estimated)
Phase: PHASE3 • Sponsor: Tesaro, Inc. • Aim: Disease control
Last updated Jun 26, 2026 12:51 UTC
GSK plc · GSK NYSE Trade on eToro (ad)Reward if it works HighA late-stage readout — success would still be major news.
Risk to the company LowA large company running many trials — it absorbs a failure here.
-
Could a One-Time cell therapy ease myasthenia gravis? new trial launches
Disease control Recruiting nowThe AURORA Study is evaluating the safety, tolerability, and efficacy of an investigational mRNA CAR T-cell therapy known as Descartes-08 in adults with acetylcholine receptor autoantibody -positive generalized myasthenia gravis. Part 1 of the study will last around 6 months. For…
Results expected Nov 2026 (estimated)
Phase: PHASE3 • Sponsor: Cartesian Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
Cartesian Therapeutics · RNAC NASDAQReward if it works HighA late-stage readout — success would transform the company.
Risk to the company HighA small company — one failure carries real weight.
-
New hep c combo aims to match top therapy in phase 3 showdown
Disease control OngoingThe purpose of this study is to compare the efficacy and safety of BEM/RZR to SOF/VEL in adults with chronic HCV.
Results expected Dec 2026 (estimated)
Phase: PHASE3 • Sponsor: Atea Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
ATEA Pharmaceuticals, Inc. · AVIR NASDAQ Trade on eToro (ad)Reward if it works HighA late-stage readout — success would transform the company.
Risk to the company HighA small company — one failure carries real weight.
-
New drug combo shows promise in High-Risk prostate cancer trial
Disease control OngoingThe purpose of this study is to determine if treatment with apalutamide plus androgen deprivation therapy (ADT) before and after radical prostatectomy (RP) with pelvic lymph node dissection (pLND) in participants with high-risk localized or locally advanced prostate cancer result…
Results expected Dec 2026 (estimated)
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
Johnson & Johnson · JNJ NYSE Trade on eToro (ad)Reward if it works HighA late-stage readout — success would still be major news.
Risk to the company LowA large company running many trials — it absorbs a failure here.
-
New drug aims to stop liver failure in NASH patients
Disease control OngoingThis study will determine the effect of oral 80 mg resmetirom administered once daily on participants with well-compensated non-alcoholic steatohepatitis (NASH) cirrhosis by measuring the time to experiencing a Composite Clinical Outcome event.
Results expected Dec 2026 (estimated)
Phase: PHASE3 • Sponsor: Madrigal Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
Madrigal Pharmaceuticals, Inc. · MDGL NASDAQ Trade on eToro (ad)Reward if it works HighA late-stage readout — success would still be major news.
Risk to the company ModerateA mid-sized company with other programmes alongside this one.
-
New hope for tough lung cancer: experimental drug takes on standard therapy
Disease control OngoingThis trial is a registered phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-B01D1 in patients with recurrent small cell lung cancer after failure of anti-PD-1/PD-L1 Monoclonal Antibodies and platinum-based chemotherapy.
Results expected Dec 2026 (estimated)
Phase: PHASE3 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
Sichuan Baili Pharmaceutical Co., Ltd. · 688506 SSEReward if it works HighA late-stage readout — success would transform the company.
Risk to the company HighA small company — one failure carries real weight.
-
New pill combo aims to keep breast cancer from returning
Disease control OngoingThis is a Phase III, randomized, double-blind, parallel, multi-center trail to evaluate the efficacy and safety of TQB3616 capsule combined with endocrine compared to placebo compared with endocrine in HR-positive and HER2-negative breast cancer adjuvant therapy. Approximately 19…
Results expected Dec 2026 (estimated)
Phase: PHASE3 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
Sino Biopharmaceutical Limited · 1177 HKEXReward if it works HighA late-stage readout — success would still be major news.
Risk to the company LowA large company running many trials — it absorbs a failure here.
-
Engineered immune cells take on Hard-to-Treat myeloma
Disease control OngoingA Phase II study of anitocabtagene-autoleucel (formerly CART-ddBCMA) for patients with relapsed or refractory multiple myeloma. Anitocabtagene-autoleucel is a BCMA-directed CAR-T cell therapy.
Results expected Dec 2026 (estimated)
Phase: PHASE2 • Sponsor: Kite, A Gilead Company • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
Gilead Sciences, Inc. · GILD NASDAQ Trade on eToro (ad)Reward if it works ModerateAn incremental result rather than a breakthrough.
Risk to the company LowA large company running many trials — it absorbs a failure here.
-
New hope for lung cancer patients who can't use standard immunotherapy alone
Disease control OngoingThe study aims to evaluate the efficacy and safety of SKB264 in combination with pembrolizumab versus chemotherapy in combination with pembrolizumab in the first-line treatment of patients with locally advanced or metastatic non-squamous NSCLC with PD-L1 negative.
Results expected Dec 2026 (estimated)
Phase: PHASE3 • Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · 6990 HKEXReward if it works HighA late-stage readout — success would still be major news.
Risk to the company ModerateA mid-sized company with other programmes alongside this one.
-
New hope for tough lung cancer: experimental drug takes on chemo
Disease control OngoingThis trial is a registered phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-B01D1 in patients with locally advanced or metastatic EGFR wild-type non-small cell lung cancer after failure of anti-PD-1/PD-L1 monoclonal antibodies and pla…
Results expected Dec 2026 (estimated)
Phase: PHASE3 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
Sichuan Baili Pharmaceutical Co., Ltd. · 688506 SSEReward if it works HighA late-stage readout — success would transform the company.
Risk to the company HighA small company — one failure carries real weight.
-
New hope for kids with rare epilepsy: drug trial targets seizure control
Disease control OngoingA Phase 3, Randomized, Multi-Center, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Relutrigine in Participants with Developmental and Epileptic Encephalopathies Followed by an Open-Label Extension
Results expected Dec 2026 (estimated)
Phase: PHASE3 • Sponsor: Praxis Precision Medicines • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
Praxis Precision Medicines · PRAX NASDAQ Trade on eToro (ad)Reward if it works Very highA late-stage readout — success would transform the company.
Risk to the company HighA small company — one failure carries real weight.
-
Can a Two-Drug attack shrink Hard-to-Treat bladder tumors?
Disease control Recruiting nowThis study is a phase II clinical study to explore the efficacy and safety of BL-B01D1 + PD-1 combination therapy in patients with locally advanced or metastatic urothelial carcinoma.
Results expected Dec 2026 (estimated)
Phase: PHASE2 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
Sichuan Baili Pharmaceutical Co., Ltd. · 688506 SSEReward if it works HighAn incremental result rather than a breakthrough.
Risk to the company ModerateA small company — one failure carries real weight.
-
Engineered immune cells take aim at a rare Protein-Clogging disease
Disease control OngoingOpen-label Phase 1b Dose Escalation/Dose Expansion study exploring the safety and efficacy of NXC-201 in patients with relapsed or refractory light chain amyloidosis (AL).
Results expected Dec 2026 (estimated)
Phase: PHASE1, PHASE2 • Sponsor: Nexcella Inc. • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
Immix Biopharma, Inc. · IMMX NASDAQ Trade on eToro (ad)Reward if it works HighAn incremental result rather than a breakthrough.
Risk to the company HighA small company — one failure carries real weight.
Not investment advice. This page lists publicly registered clinical trials and the companies running them, for information only. A trial finishing is not a result, and a result is not an approval. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to a broker we have a commercial relationship with, and we may earn a commission if you open an account. This never affects which trials are listed or how they are ranked.